Fina Health Addresses End of Tirzepatide and Semaglutide Shortages Amid Continued High Costs

Image: https://www.abnewswire.com/upload/2025/03/43f821b943f17653ce138b87e8b60170.jpg

Miami, FL - March 17, 2025 - The recent conclusion of the nationwide shortage of popular weight-loss medications Tirzepatide and Semaglutide has done little to ease patient struggles, as high prescription costs persist, creating significant barriers to treatment. In response, Fina Health, a leader in comprehensive telehealth weight-loss solutions, has amplified its commitment to empowering patients through conservative, sustainable health measures.

While the medication shortage was challenging, its resolution has not translated into affordability for many patients, with pricing remaining prohibitively high. Recognizing this ongoing issue, Fina Health emphasizes evidence-based, conservative treatments including dietary guidance, personalized exercise regimens, and professional nutritional counseling to ensure sustainable weight loss results.

"Our mission at Fina Health has always been to deliver holistic care that promotes lasting wellness," said Dr. Sam Searcy, founder of Fina Health. "While we recognize the value of medications like Tirzepatide and Semaglutide, we firmly believe in optimizing conservative measures first, empowering patients with practical tools and lifestyle adjustments that lead to sustainable, long-term success."

Fina Health's integrative approach combines telehealth convenience with personalized lifestyle management, ensuring patients receive comprehensive care that addresses both short-term needs and long-term health goals.

For more information about Fina Health's holistic weight-loss solutions, please visit finamd.com

About Fina Health:

Fina Health is a telehealth platform based in Florida, dedicated to providing accessible, comprehensive weight-loss solutions. Emphasizing conservative approaches such as dietary education, exercise planning, and nutritional counseling, Fina Health empowers patients to achieve lasting wellness through sustainable health strategies.

Media Contact
Company Name: Fina Health
Contact Person: Sam Searcy
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=fina-health-addresses-end-of-tirzepatide-and-semaglutide-shortages-amid-continued-high-costs]
Phone: 1-645-223-7888
City: Miami
State: FL 33137
Country: United States
Website: http://finamd.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.